Bioventus (NASDAQ:BVS) Issues FY 2026 Earnings Guidance

Bioventus (NASDAQ:BVS) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.750-0.790 for the period, compared to the consensus EPS estimate of 0.780. The company issued revenue guidance of $590.0 million-$595.0 million, compared to the consensus revenue estimate of $604.6 million.

Bioventus Stock Up 4.4%

Shares of BVS opened at $11.42 on Thursday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.17 and a current ratio of 1.68. Bioventus has a one year low of $6.47 and a one year high of $15.89. The stock has a market capitalization of $960.31 million, a price-to-earnings ratio of 14.03, a PEG ratio of 1.40 and a beta of 0.66. The stock has a 50 day moving average price of $13.57 and a 200 day moving average price of $10.94.

Bioventus (NASDAQ:BVS) last announced its quarterly earnings data on Monday, November 2nd. The company reported $0.17 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.17. Bioventus had a return on equity of 26.31% and a net margin of 9.78%. The company had revenue of $142.44 million for the quarter. Equities research analysts forecast that Bioventus will post 0.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Barrington Research set a $18.00 price objective on shares of Bioventus in a report on Thursday, August 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 price objective on shares of Bioventus in a research report on Monday, August 17th. Craig Hallum reissued a “buy” rating and set a $18.00 price objective on shares of Bioventus in a research report on Thursday, August 6th. Canaccord Genuity Group reduced their price objective on shares of Bioventus from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Weiss Ratings raised shares of Bioventus from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Six equities research analysts have rated the stock with a Buy rating. According to MarketBeat.com, Bioventus presently has an average rating of “Buy” and an average target price of $16.60.

Bioventus News Roundup

Here are the key news stories impacting Bioventus this week:

• Positive Sentiment: Canaccord Genuity kept its “buy” rating, while lowering its price target from $19 to $18. Canaccord Genuity price target update
• Neutral Sentiment: Third-quarter EPS of $0.17 matched consensus, and the company reported higher profit. However, earnings growth was attributed largely to debt paydown rather than stronger operations. Bioventus Q3 profit and outlook report
• Negative Sentiment: Third-quarter sales missed expectations, and Bioventus cut its 2026 revenue outlook to $590 million–$595 million from a consensus estimate of $604.6 million. The reduced forecast is the main near-term concern for investors. Bioventus shares and Q3 outlook
• Negative Sentiment: The company maintained its 2026 EPS guidance of $0.75–$0.79, broadly in line with the $0.78 consensus, but that does not offset the weaker revenue outlook. Bioventus 2026 guidance

About Bioventus

Bioventus Inc is a medical device and biologics company focused on developing and commercializing products that support bone healing, joint health and surgical recovery. Its portfolio is designed to help healthcare professionals treat musculoskeletal conditions and improve patient outcomes through noninvasive therapies, injectable products and biologic solutions.

The company’s offerings include bone stimulation systems such as EXOGEN, which is used to support fracture healing, as well as injectable osteoarthritis treatments including DUROLANE and GELSYN-3.